New combo therapy for diabetes shows promise in Year-Long trial
NCT ID NCT02227849
First seen Jan 11, 2026 · Last updated May 19, 2026 · Updated 20 times
Summary
This study looked at the long-term safety and effectiveness of adding canagliflozin to an existing GLP-1 treatment in 71 adults with type 2 diabetes. Over 52 weeks, researchers tracked side effects, blood sugar control, weight, and blood pressure. The goal was to see if the combination helps manage diabetes without major safety concerns.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Reserch site
Chūbu, Japan
-
Reserch site
Hokkaido, Japan
-
Reserch site
Kanto, Japan
-
Reserch site
Kinki, Japan
Conditions
Explore the condition pages connected to this study.